Healthcare
Genmab A/S(GNMSF)
Live Price
Offline$249.28
+0.00% today
1Y Change
+21.96%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $16.28B
- Revenue Growth
- -82.1%
- EPS Growth
- -86.9%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genmab A/S (GNMSF) is a Healthcare stock with a market cap of $16.28B and listed on OTC. The stock last traded around $249.28 and up 22.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -82.1%, EPS growth of -86.9%, a dividend yield of 0.0%. What stands out right now is revenue -82.1%, EPS -86.9%, free cash flow -84.3% with operating margin 36.7% and ROIC 50.3%. Valuation is more restrained than many high-expectation growth names at P/E 4.2 and price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GNMSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-82.1% vs +7.6% peer median
Operating Margin
Above sector median
+36.7% vs +19.4% peer median
P/E
Below sector median
4.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -82.1% and EPS is at -86.9%, with operating margin around 36.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -4.2% | -2.0% | -7.8% |
2026 Feb 17, 2026 | -81.8% | -4.3% | -2.4% | -7.6% |
2025 Nov 6, 2025 | +32.9% | +1.9% | +6.7% | +12.6% |
Benchmark Edge
GNMSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNMSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNMSF Max Drawdown
-33.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GNMSF and SPY.
Company Overview
Genmab A/S
Other OTC
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
- Leadership
- Jan van de Winkel
- IPO Date
- Jan 5, 2010
- Employees
- 2.6k
- Street Address
- Kalvebod Brygge 43
- Mailing
- Copenhagen, 1560
- Region
- Copenhagen, DK
- Reporting Currency
- USD
- Investor Line
- 45 70 20 27 28
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 4.2
- EV/EBITDA
- 3.7
- Price/Sales
- 0.9
- Price/Book
- 2.8
Growth
- Revenue
- -82.1%
- EPS
- -86.9%
- Free Cash Flow
- -84.3%
Profitability
- Gross Margin
- 94.0%
- Operating Margin
- 36.7%
- Net Margin
- 21.0%
- ROE
- 19.0%
- ROIC
- 50.3%
Balance Sheet
- Debt/Equity
- 0.95
- Current Ratio
- 2.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.